Basic Sciencemoderate evidence
Homoharringtonine exhibits senotherapeutic activity that mitigates diet- and age-associated obesity and insulin resistance and extends lifespan in mice.
Nature communications·March 31, 2026·PMID 41916993
Why it mattersSenescent cell accumulation in adipose tissue drives age-related metabolic decline and obesity-related insulin resistance. Identifying a repurposed FDA-approved drug that can clear these cells and improve metabolic health in preclinical models offers a potential translational path for targeting aging and metabolic disease.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled